Preclinical scientific tests recommend that retatrutide may affect weight problems-associated most cancers progression. In the study led by Marathe et al., retatrutide-induced fat loss decreased tumor engraftment, delayed tumor onset, and appreciably attenuated tumor expansion in pancreatic and lung